Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Quarterly Shareholder Update Webinar – Q1 FY2026

20 October 2025 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to advise it will host an investor webinar at 1:00pm AEDT (10:00am AWST) on Friday, 31 October 2025.

During the webinar Neurizon Team will provide an overview of the September Quarterly Activities Report, together with the latest update on the regulatory progress and near-term clinical development pathway for the Company's lead asset, NUZ-001. The briefing will be followed by a Q&A session.

Anyone wishing to attend the webinar must register via the following link:

Registration: https://bit.ly/NUZ1025

Date and time: 1:00pm AEDT (10:00am AWST) on Friday, 31 October

Everyone is encouraged to submit questions ahead of the event via the registration page or via enquiries@neurizon.com email. A recording will be made available on www.neurizon.com following the session for those unable to attend live.

This webinar forms part of Neurizon's commitment to open and transparent communication with shareholders as we continue to advance our mission of delivering meaningful progress for people living with neurodegenerative diseases.

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.
For further information, please contact:

Dr. Michael Thurn
Managing Director and Chief Executive Officer
Neurizon Therapeutics Limited
enquiries@neurizon.com
+61 (3) 9692 7222

Lidija Damjanovic
Head of Marketing and Corporate Affairs
Neurizon Therapeutics Limited
lidija@neurizon.com
+61 (0) 425 700 504

Released through: Henry Jordan, Six Degrees Investor Relations, +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com

Neurizon® is a registered trademark of Neurizon Therapeutics Limited